NMT PHARMA has participated in 2017 ASCO Annual Meeting held from 2ndto 6th June 2017 at McCormick Place, Chicago, USA. More than 38,000 oncology professionals from around the world attended this event presenting and discussing the latest research in treatment and patient care. This is a warm-up event for NMT Pharma as its clinical trial Phase 1 program of camptothecin analogue innovative drug CZ48 will be completed in 2018. The clinical data will be presented in ASCO meeting when it is available.
NMT PHARMA Participates in 2017 ASCO Annual Meeting in Chicago, June 2nd to 6th, 2017
2017, December 19